These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24517157)

  • 1. Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.
    van Veen JJ; Maclean RM; Hampton KK; Hamer A; Makris M
    Haemophilia; 2014 Jul; 20(4):587-92. PubMed ID: 24517157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
    Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
    Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
    Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
    Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature.
    Obergfell A; Auvinen MK; Mathew P
    Haemophilia; 2008 Mar; 14(2):233-41. PubMed ID: 18081827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
    Holmström M; Tran HT; Holme PA
    Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
    Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.
    Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Alvarez-Roman M; Martin-Salces M; Rodriguez de la Rua A
    Haemophilia; 2010 May; 16(102):84-8. PubMed ID: 20536990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
    Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C
    Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.